Policosanol: A new treatment for cardiovascular disease?

Alternative Medicine Review

Volumn 7, Issue 3, 2002, Pages 203-217

  Janikula, Mark ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; POLICOSANOL; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; REVIEW; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR SYSTEM; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CUBA; DIABETES MELLITUS, TYPE 2; FATTY ALCOHOLS; FEMALE; HEART DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; SEX FACTORS;

EID: 0036304788     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia
2. Effect of policosanol on serum lipid and lipoproteins in healthy volunteers
3. Efficacy and safety of policosanol in patients with primary hypercholesterolemia
4. Effect of successive dose increases of policosanol on the lipid profile and tolerability of treatment
5. One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia
6. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment
7. One-year study of the effect of policosanol on lipid profile in patients with type II hypercholesterolemia
8. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia
9. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia
10. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
11. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12-month study
12. Effects of policosanol in hypertensive patients with type II hypercholesterolemia
13. Effect of policosanol on hyperlipidemia and coronary heart disease in middle-aged patients. A 14-month pilot study
14. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
15. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk
16. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: A 6-month double-blind study
17. Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study
18. Treatment of hypercholesterolemia in NIDDM with policosanol
19. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus
20. Effects of policosanol on postmenopausal women with type II hypercholesterolemia
21. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women
22. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function
23. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia
24. A comparative study on the efficacy and tolerability of policosanol and simvastatin for treating type II hypercholesterolemia
25. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia
26. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients
27. Efficacy and tolerability of policosanol compared with lovasatin in patients with type II hypercholesterolemia and concomitant coronary risk factors
28. A comparative study of policosanol versus probucol in patients with hypercholesterolemia
29. A comparative study of policosanol versus acipimox in patients with type II hypercholesterolemia
30. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation
31. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro
32. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers
33. Effect of policosanol on platelet aggregation in healthy volunteers
34. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers
35. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers
36. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients
37. Effect of policosanol on intimal thickening in rabbit cuffed carotid artery
38. A comparative study of policosanol vs. lovastatin on intimal thickening in rabbit cuffed carotid artery
39. Functional improvement in coronary artery disease after 20 months of lipid-lowering therapy with policosanol
40. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients
41. Doppler-ultrasound pilot study of the effects of long-term policosanol therapy on carotidvertebral atherosclerosis
42. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new specific activity scale
43. A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk
44. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication
45. A long-term study of policosanol in the treatment of intermittent claudication
46. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats
47. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts
48. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts
49. Policosanol: Results of a postmarketing surveillance study of 27,879 patients
50. Pharmacoepidemiologic study of policosanol
51. A 12-month study of policosanol oral toxicity in Sprague Dawley rats
52. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study
53. Toxicity of policosanol in beagle dogs: One-year study
54. Effects of policosanol chronically administered in male monkeys (Macaca arctoides)
55. Carcinogenicity of policosanol in mice: An 18-month study
56. Evaluation of peri- and post-natal toxicity of policosanol in rats
57. Teratogenic and reproductive studies of policosanol in the rat and rabbit
58. Multigeneration reproduction study of policosanol in rats